Check Cap Ltd (NASDAQ:CHEK) has received an average broker rating score of 1.50 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company. Check Cap’s rating score has declined by 50% from three months ago as a result of a number of analysts’ ratings changes.
Brokers have set a 1 year consensus target price of $10.50 for the company and are anticipating that the company will post ($0.47) EPS for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 101 out of 255 based on the ratings given to related companies.
Several analysts have recently commented on CHEK shares. Zacks Investment Research cut Check Cap from a “hold” rating to a “sell” rating in a report on Thursday, January 3rd. HC Wainwright set a $14.00 target price on Check Cap and gave the company a “buy” rating in a report on Friday, December 14th. Finally, Dougherty & Co started coverage on Check Cap in a research note on Tuesday, February 5th. They set a “buy” rating and a $6.00 price objective on the stock.
Check Cap (NASDAQ:CHEK) last issued its quarterly earnings results on Thursday, March 28th. The medical research company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.04). As a group, equities analysts predict that Check Cap will post -1.7 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Check Cap stock. Dimensional Fund Advisors LP acquired a new position in shares of Check Cap Ltd (NASDAQ:CHEK) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 35,131 shares of the medical research company’s stock, valued at approximately $141,000. Dimensional Fund Advisors LP owned approximately 2.20% of Check Cap at the end of the most recent quarter.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Featured Story: What is a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.